Abstracts presented at ASCO GU examined whether the radioligand therapy impacts or is affected by ARPIs or chemotherapy.

Researchers will test the cell therapy in a dozen patients with CD19-expressing blood cancers, including diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia.

NEW YORK – Hepion Pharmaceuticals has acquired the rights to develop Cirna Diagnostics' circulating tumor RNA (ctRNA) biomarker assay that can detect early, high-risk hepatocellular carcinoma, the ...

The company is a spinoff of Avidity Biosciences, which was acquired by Novartis. The formation of the new firm was a condition of that acquisition.